Literature DB >> 15833067

Cell therapies for neurological disease--from bench to clinic to bench.

Timothy Harrower, Roger A Barker.   

Abstract

The lack of any meaningful regeneration in the adult central nervous system (CNS) subsequent to damage or degeneration stimulated the concept of replacement of the deficient cells by transplantation. Thus, much time and effort has been spent on investigating the potential of cell replacement therapy for repair in a range of conditions of the CNS over the last 25 years. As promising proof of principle basic science results were slowly converted to success in clinical transplantation trials in Parkinson's disease (PD), the future seemed very encouraging for cell therapy. However, the recent randomised, double-blind, placebo-controlled studies of fetal neural transplantation in PD have produced more equivocal results, which has dampened enthusiasm for this approach. However, whilst the translation of cell therapies to the clinic is in limbo, the emergence of stem cells as a source of the replacement tissue has revitalised the laboratory-based studies. This paper attempts to reconcile these disparate views and put forward the authors' view on the future of this form of biological therapy and its implications for related therapies.

Entities:  

Mesh:

Year:  2005        PMID: 15833067     DOI: 10.1517/14712598.5.3.289

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  2 in total

1.  Species-dependent differences of embryonic stem cell-derived neural stem cells after Interferon gamma treatment.

Authors:  Janine Walter; Marcel Dihné
Journal:  Front Cell Neurosci       Date:  2012-11-08       Impact factor: 5.505

2.  Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression.

Authors:  Emily N Cronin-Furman; M Kathleen Borland; Kristen E Bergquist; James P Bennett; Patricia A Trimmer
Journal:  Mol Neurodegener       Date:  2013-01-26       Impact factor: 14.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.